格隆汇APP·2025-05-29 10:14Core Viewpoint - The article highlights a significant bullish trend in the A-share market, particularly in the innovative pharmaceutical sector, driven by favorable news regarding U.S. tariffs and strong market sentiment [1][10][12]. Market Performance - On May 29, major A-share indices rose, with the Shanghai Composite Index up 0.7% to 3363 points, the Shenzhen Component up 1.24%, and the ChiNext Index up 1.37%. Nearly 4500 stocks rose, with over a hundred hitting the daily limit [1]. - The financial technology, innovative pharmaceuticals, internet, and semiconductor sectors showed strong performance, with the innovative pharmaceutical sector experiencing the most significant gains [2][6]. Innovative Pharmaceutical Sector - The innovative pharmaceutical sector saw substantial price increases, with companies like Ruizhi Pharmaceutical, Shuyou Pharmaceutical, and Yifang Bio achieving 20% daily limits. Over ten other pharmaceutical stocks rose more than 10% [2][3]. - The Hang Seng Pharmaceutical ETF rose by 3.61%, with a year-to-date increase of 36.93%, while the newly launched Sci-Tech Pharmaceutical ETF gained 4% [5]. Tariff News Impact - A major positive development was the U.S. International Trade Court's decision to block the implementation of tariffs announced by Trump, which could significantly benefit Chinese pharmaceutical companies by alleviating concerns over high tariffs on medical supplies and APIs [10][11][15]. - The court's ruling is expected to create a more stable legal environment for Sino-U.S. pharmaceutical trade and technology cooperation, reducing potential risks for Chinese innovative drug companies [16]. Growth in License-out Transactions - There has been a notable increase in license-out transactions for Chinese pharmaceutical companies, with 94 deals totaling $51.9 billion completed in 2024, marking a 26% year-on-year growth. The first quarter of 2025 alone saw 41 transactions worth $36.9 billion [19]. - Major companies like Hengrui Medicine and Innovent Biologics have signed significant commercialization agreements, further boosting market confidence in the innovative pharmaceutical sector [20]. ASCO Conference and Clinical Trials - The upcoming ASCO conference is expected to showcase numerous innovative drug companies, with 71 original research results from Chinese firms selected for presentation, indicating the rapid rise of Chinese innovative drug enterprises [21][22]. - The oncology sector remains a focal point for innovation, with a significant portion of clinical trials and transactions centered around cancer treatments, reflecting the industry's growth potential [22]. Investment Opportunities - Despite recent strong performance, there are still numerous opportunities within the innovative pharmaceutical sector for long-term investment, particularly in companies with robust pipelines and significant market potential [24][25]. - The article suggests that investing in related ETFs, such as the Hang Seng Pharmaceutical ETF and the Sci-Tech Pharmaceutical ETF, may be a prudent strategy for those interested in the innovative pharmaceutical sector [27][30]. Market Sentiment and Fund Inflows - The innovative pharmaceutical sector has seen increased interest from institutional investors, with a 62% quarter-on-quarter increase in the total market value held by funds in the sector, reaching 57.6 trillion yuan [31][32].